Who We Are
Corporate Profile
Oranda Therapeutics is a focused rare disease company dedicated to improving sustainable access to established and innovative new medicines across Europe.
Our Strategy
CorporateStrategy
Commercialise established rare disease medicines
- Portfolio of 8 generic rare disease medicines
- First revenues expected Q2 2026
- Revenue target >€50m by 2028
In-license, co-develop and commercialise novel rare disease assets
- Active pipeline evaluation and business development
- Focus on rare diseases with high unmet need
- Partnership-led approach to de-risk development
Questions & Answers
See the Corporate Strategy section above.
Oranda is currently focused on rare endocrinology and cardio-respiratory conditions.
Details of our funding rounds will be announced in due course.
Please see our events section.
Please complete a Contact form and we will be happy to discuss.